Offer - Urjas Oil for just ₹ 1 X
Tazid 250 Injection is a commercial drug that is prescribed in the form of Injection. Skin Infections, Pneumonia are some of its major therapeutic uses. The alternative uses of Tazid 250 Injection have also been explained below.
The correct dosage of Tazid 250 Injection depends on the patient's age, gender, and medical history. Besides the medical condition it is advised for, the route of administration also plays an important role in determining the correct drug dosage. Detailed information has been provided in the dosage section.
Apart from the aforementioned side effects, Tazid 250 Injection can also lead to other problems, which have been listed below. These side effects of Tazid 250 Injection are usually temporary and subside with the completion of treatment. Please speak with your doctor if these side effects worsen or persist for a longer duration.
It is also important to note that Tazid 250 Injection has a Safe effect for pregnant women and Safe effect on lactating mothers. In addition, Tazid 250 Injection's effects on the liver, heart and kidney are discussed below in the Tazid 250 Injection related warnings section.
Individuals suffering from medical conditions like Kidney Disease must refrain from the use of Tazid 250 Injection since this can cause severe adverse effects. The section on Tazid 250 Injection contraindications lists all such conditions.
Besides this, Tazid 250 Injection may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Tazid 250 Injection is considered not safe while driving, and is not addictive.
Tazid 250 Injection is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Tazid 250 Injection safe for pregnant women?
Pregnant women can take Tazid safely.
Is the use of Tazid 250 Injection safe during breastfeeding?
Breastfeeding women can safely use Tazid.
What is the effect of Tazid 250 Injection on the Kidneys?
Tazid has very mild side effects on the kidneys.
What is the effect of Tazid 250 Injection on the Liver?
There are no any side effects of Tazid on the liver.
What is the effect of Tazid 250 Injection on the Heart?
Using Tazid does not have any harmful effects on the heart.
If you are suffering from any of the following diseases, you should not take Tazid 250 Injection unless your doctor advises you to do so -
Is this Tazid 250 Injection habit forming or addictive?
No, you will not get addicted to Tazid 250 Injection.
Is it safe to drive or operate heavy machinery when consuming?
After taking Tazid 250 Injection, you should not drive or work on any heavy machine, as Tazid 250 Injection can make you drowsy.
Is it safe?
Yes, but consume Tazid 250 Injection only on doctor's advice.
Is it able to treat mental disorders?
There is no benefit of taking Tazid 250 Injection for mental disorders.
Interaction between Food and Tazid 250 Injection
You can take Tazid 250 Injection with food.
Interaction between Alcohol and Tazid 250 Injection
Information about the interaction of Tazid 250 Injection and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; FORTAZ® (ceftazidime)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 728
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 307-312